rhBMP-2 placement

PreclinicalBiologic

AAya Adil Saeed

rhBMP-2 placement is one of 8 biologic programs targeting Bone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BoneActive, not recruiting

BonePreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bone

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

BOOST Cells

KKarolinska Institutet

Phase 2

1 3

Bone Marrow Aspirate Concentrate

MMassachusetts General Hospital

Preclinical

2 4

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 5

Vertebral Bone Marrow Clot

IIstituto Ortopedico Rizzoli

Preclinical

1 6

rhBMP-2 placement

AAya Adil Saeed

Preclinical

1 7

Puregen Osteoprogenitor Cell Allograft

AAlphatec Spine, Inc.

Preclinical

1 8

Elelyso

SShaare Zedek Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone1 trial

BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement

Active, not recruiting·AAya Adil Saeed·N/A·NCT07240493·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rhBMP-2 placement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhBMP-2 placement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhBMP-2 placement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aya Adil Saeed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAya Adil Saeed

rhBMP-2 placement

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone1 trial

References

Drug Info

Quick Facts

Related News